Motavizumab

From Wikipedia, the free encyclopedia
Motavizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target RSV glycoprotein F
Clinical data
Trade names Numax
Legal status ?
Routes i.v.
Pharmacokinetic data
Protein binding None
Identifiers
CAS number 677010-34-3 N
ATC code J06BB17
UNII 50Y163LK8Q YesY
KEGG D06621 YesY
Chemical data
Formula C6476H10014N1706O2008S48 
Mol. mass Approximately 148 kDa
 N (what is this?)  (verify)

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.[1]

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[2]

References

  1. ↑ ClinicalTrials.gov
  2. ↑ "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21. 

External links

Monoclonal antibodies for infectious disease and toxins
Fungal ("-fung-")
Human ("-fungu-")
Viral ("-vi(r)-")
Human ("-viru-")
Humanized ("-vizu-")
Bacterial ("-ba(c)-")
Human ("-bacu-")
Mouse ("-baco-")
Chimeric ("-baxi-")
Humanized ("-bazu-")
Toxin ("-tox(a)-")
Human ("-toxu-")
Humanized ("-toxazu-")
Immune sera and immunoglobulins (J06)
Polyclonal antibodies
Monoclonal antibodies

M: BAC

bact (clas)

gr+f/gr+a (t)/gr-p (c)/gr-o

drug (J1p, w, n, m, vacc)


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.